Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.

The Journal of clinical psychiatry - 1 Jun 2009

Volpi Simona, Potkin Steven G, Malhotra Anil K, Licamele Louis, Lavedan Christian

Abstract excerpt

OBJECTIVE: To demonstrate how several polymorphisms previously associated with the efficacy of the novel antipsychotic iloperidone could be used together to predict clinical response and provide practical information for individualized treatment. METHOD: This inpatient randomized, double-blind, placebo- and ziprasidone-controlled, 28-day study of the efficacy of iloperidone was conducted from November 2005 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoxazoles

Share to Piperazines

Share to Piperidines

Share to Psychiatric Status Rating Scales

Share to Psychometrics

Share to Thiazoles

Source

Identifiers

PMID: 19573479
DOI: 10.4088/jcp.08m04391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.PMID 19573479Read ↗

Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.Semantic proximity Read ↗

Iloperidone: A new drug for the treatment of schizophrenia.Semantic proximity Read ↗

A computational algorithm for personalized medicine in schizophrenia.Semantic proximity Read ↗

Toward understanding genetic risk for differential antipsychotic response in individuals with schizophreniaSemantic proximity Read ↗

COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy.Semantic proximity Read ↗

Pharmacogenetics and outcome with antipsychotic drugsSemantic proximity Read ↗

Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.Semantic proximity Read ↗

Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.Semantic proximity Read ↗

SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Semantic proximity Read ↗

Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness.Semantic proximity Read ↗

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.Semantic proximity Read ↗

Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.